We investigated the efficacy of nivolumab treatment in patients with metastatic renal cell carcinoma who discontinued nivolumab treatment due to reasons other than disease progression. Of the 34 patients, 3 patients discontinued nivolumab therapy due to adverse events and were subsequently observed without additional treatment. The first patient discontinued nivolumab after 14 cycles of treatment due to type 1 diabetes mellitus and has maintained partial remission for 8 months. The second patient discontinued nivolumab after 11 cycles of treatment due to interstitial pneumonitis, and durable response was confirmed for 5 months. However, multiple lung lesions reappeared at 6 months after discontinuing nivolumab. The third patient discontinued nivolumab due to elevated liver enzymes after three cycles of treatment. At the time of discontinuation, a new liver lesion appeared, but the lesion decreased in size at 6 months after discontinuation. In the present study, a relatively durable response was observed in three patients who discontinued nivolumab without additional treatment.
Introduction
Nivolumab therapy is recommended as second-line systemic therapy for patients with unresectable or metastatic renal cell carcinoma (RCC) according to several guidelines (1, 2) . Systemic therapy for metastatic RCC, including molecular targeted therapy, is basically continued for patients who achieve partial or complete remission with metastatic RCC given that they experience acceptable drug tolerability. However, systemic therapy is sometimes discontinued due to reasons other than disease progression such as side effects.
One phase one study that assessed nivolumab therapy in patients with advanced RCC provided details on four patients who discontinued therapy for reasons other than disease progression. Following treatment discontinuation in these four patients, treatment responses lasted an additional 19, 45, 51 and 59 weeks, respectively, after discontinuation (3). However, there are few reports describing disease status after discontinuation of nivolumab therapy as presented above. In the present study, we discuss three patients who discontinued nivolumab therapy due to adverse events and who were subsequently observed without additional treatment.
Patients and methods
An institutional review board approved this retrospective review of consecutive patients who received nivolumab therapy for metastatic RCC at a single institution. Of the 34 patients who received nivolumab therapy between 2016 and 2017, 3 patients who discontinued nivolumab therapy due to adverse events and who were observed without additional treatment were retrospectively analyzed.
Tumors were staged according to the TNM system (4) and graded according to Fuhrman's classification (5) . The pathological subtype of the tumors was defined according to the 2016 World Health Organization (WHO) classification of urogenital tumors (6) . The metastatic RCC risk classification was in accordance with the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model (7).
Results
Of the 34 patients who received nivolumab therapy for metastatic RCC, three (10%) patients discontinued nivolumab therapy due to reasons other than disease progression. These three patients were observed without additional treatment. Table 1 provides the treatment summary in three cases.
Case 1
Our first patient was a 72-year-old male who underwent left radical nephrectomy at the age of 65. The pathological findings indicated clear-cell RCC, pT1a, and Fuhrman grade 1 carcinoma. Six years after surgery, multiple lung metastasis appeared, and the patient commenced interferon alpha (INFa) therapy. After a relapse occurred with INFa therapy, the patient received interleukin 2 (IL-2), sorafenib and axitinib therapy, but the disease progressed with each medication. Nine years following the administration of his first systemic therapy, he started nivolumab therapy and the IMDC risk model indicated that he was at intermediate risk. The targeted lesion in his lung was confirmed to be reduced by 50% by CT findings, which was regarded as partial remission 2 months after the first administration of nivolumab therapy. After 14 cycles of nivolumab therapy, he was diagnosed with type 1 diabetes mellitus, an immune-related adverse event of nivolumab. The patient refused to continue nivolumab and was observed without additional systemic therapy. So far, the disease has not progressed 8 months after discontinuation of nivolumab therapy.
Case 2
Our second patient was a 65-year-old male who underwent left radical nephrectomy at the age of 59. His pathological findings indicated clear-cell RCC, pT3, and Fuhrman grade 3 carcinoma. At 6 months following surgery, lung metastasis appeared, and he underwent metastasectomy of the lung metastasis. Despite his surgery, he experienced other lung metastasis and bone metastasis, and sequentially received sunitinib (8 months), pazopanib (5 months), axitinib (9 months) and everolimus (6 months) and sunitinib (6 months) therapy. The disease progressed despite each treatment and subsequently, the patient was started on nivolumab therapy. At the second month after his first administration of nivolumab, the lung lesions almost disappeared, and his bone metastasis was well controlled. After 11 cycles of nivolumab therapy, he was diagnosed with interstitial pneumonitis and therefore received steroid therapy for 1 month. The patient was then observed without another treatment. Small multiple lung lesions appeared 6 months after discontinuation of nivolumab therapy at which time he was started on temsirolimus.
Case 3
The third patient was a 53-year-old male patient who was diagnosed with left RCC with inferior venous cava (IVC) thrombosis and multiple lung metastases. He underwent left radical nephrectomy with IVC thrombectomy. Pathological findings indicated papillary RCC, type 2, pT3b and Fuhrman grade 3 carcinoma. He commenced pazopanib therapy after surgery, but it was discontinued due to elevated liver enzymes that were observed 1 month after starting pazopanib. The disease progressed despite second-line therapy of axitinib for 7 months. The patient was subsequently started on nivolumab therapy but it was discontinued due to elevated liver enzymes after three cycles. Although his liver function recovered, he was observed without an alternate treatment as this was a requirement of his antituberculosis treatment. At the time nivolumab therapy was discontinued, his lung metastasis was decreased in size but liver metastasis appeared. And 6 months after the discontinuation of nivolumab, lung metastasis ( Fig. 1 ) and liver metastasis (Fig. 2 ) decreased in size without additional treatment (Fig. 3) .
Discussion
Our study presented three patients who experienced durable treatment response for metastatic RCC after discontinuation of nivolumab treatment. Although one of the three patients had disease progression at 6 months after discontinuation of nivolumab, the remaining two patients have experienced a preserved response to nivolumab more than 6 months after discontinuation. Moreover, the third patient had disease progression during nivolumab therapy; however, the targeted liver lesion reduced in size after discontinuation of nivolumab therapy.
Durable response of immune checkpoint drugs has been reported in several studies on malignant solid tumors (3, (8) (9) (10) . Regarding RCC, David and colleagues reviewed 34 patients with nivolumab therapy and reported that 10 patients (29%) achieved objective responses, with a median response duration of 12.9 months. An additional nine patients (27%) demonstrated stable disease lasting >24 months (3). In addition, a phase 2 trial of nivolumab for metastatic RCC revealed that approximately 20% of patients achieved an objective response rate, and median duration of response was not reached in the 0.3 mg/kg and 2 mg/kg groups and was 22.3 months in the 10 mg/kg group (10).
As for disease status after discontinuation of nivolumab therapy for reasons other than progressive disease, a few articles discussed this issue (3, 8, 9) . McDermott and colleagues reported on four patients with metastatic RCC who discontinued nivolumab for reasons other than disease progression and were observed without additional treatment (3) . Treatment responses in these four patients lasted an additional 19, 45, 51 and 59 weeks after discontinuation. Regarding nivolumab therapy for advanced non-small-cell lung cancer, Gettinger and colleagues reported that 18 patients who received nivolumab treatment discontinued nivolumab for reasons other than progressive disease; nine patients (95%) had responses lasting > 9 months after their last dose (8) . In addition, the KEYNOTE-001 study showed durable complete response after discontinuation of pembrolizumab, another programmed death 1 immune checkpoint inhibitor, in patients with metastatic melanoma (9) . Among 67 patients who achieved complete response and proceeded to observation without additional anticancer therapy, the 24-month disease-free survival rate from time to CR was 89.9%.
The third patient discontinued nivolumab therapy due to elevated liver enzymes. Following this, a new lesion in the liver appeared; however, the targeted lung lesion regressed. This indicated progressive disease at the time nivolumab therapy was discontinued. However, the liver lesion decreased in size after the discontinuation of nivolumab. Immune-related radiographic responses such as a persistent reduction in target lesions with the presence of new lesions or regression of targeted lesions after initial growth were reported in 5% of patients with non-small-cell lung cancer (8) . This type of unconventional response pattern will require clinicians to alter their approach to assessing patients who receive immunotherapy. Regarding RCC, immune-related radiographic responses were found in the phase 3 CheckMate 025 study (11) . In this study, of the 406 nivolumab-treated patients, disease progression was noted in 316 (78%) according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Of those who showed progression, 153 (48%) patients were treated beyond progression, 31 had a complete or partial response and 51 had stable disease.
The three patients had a relatively durable response after discontinuation of the nivolumab therapy. However, it is possible that the response was affected by other agents associated with the patient's treatment history. Patient 1 developed lung metastasis 6 years after a nephrectomy and received sequential systemic therapy of INFa, IL-2, sorafenib, and axitinib for 9 years until he started nivolumab therapy, which implies that the tumor had a slow growing nature. Durable responses after the discontinuation of nivolumab may be related to the tumor's slow growing nature in addition to the nivolumab's effect. Patient 2 received steroid therapy for 1 month to treat interstitial pneumonitis. The steroidal antitumor effect may be associated with a stable disease status after discontinuation of nivolumab.
Our study has several limitations. It is a retrospective study conducted at a single institution that consisted of three patients, which is a small cohort. However, reports describing the disease status after discontinuation of nivolumab therapy without additional treatment are very rare, especially regarding RCC. Therefore, our study will serve as a useful reference for clinicians and patients who discontinue nivolumab therapy for reasons other than disease progression.
In conclusion, a relatively durable response was observed in three patients after discontinuing nivolumab treatment. Further studies and observations are required to better understand the patients who achieve durable responses to immune-oncological drugs after discontinuing them.
